Veronica Calvo Vidal, Ph.D., is a highly motivated and innovative cell biologist with over eight years of experience in the study of mechanisms of cancer and metastasis progression, mainly focused on finding new therapeutic approaches against this life-threatening endpoint. Prior to joining HiberCell, Veronica joined the Myeloid Immunobiology group at Lilly Research Laboratories to expand the understanding of the immune system’s role in controlling metastatic disease. During this time, she effectively led and prioritized multiple research projects in the dormancy and minimal residual disease field, resulting in several peer-reviewed publications and manuscripts in preparation. Prior to that, after briefly working on two projects regarding HER2+ breast cancer mechanisms of therapeutic resistance and TNBC vulnerabilities, she joined Dr. Julio Aguirre-Ghiso laboratory at the Icahn School of Medicine at Mount Sinai in New York to lead the pre-clinical testing of anti-metastatic drugs. Based on this work, Veronica received the Lilly Innovative Fellowship Award in 2015. One constant in Dr. Calvo Vidal’s career has been a relentless focus on translating basic in vitro and in vivo biology data into opportunities for therapeutic intervention in different cancer indications.
Dr. Calvo Vidal received her B.Sc. in pharmacy/biochemistry from Barcelona University in Spain and her Ph.D. in biomedicine from Pompeu Fabra University’s Center for Genomic Regulation focused on finding new vulnerabilities of BRCA1+ breast cancer disease.